North America Clinical Trials Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The North America Clinical Trials Market is segmented By Phase, By Design (Treatment Studies and Observational Studies) and Geography.

Market Snapshot

Image1_North America Clinical Trials Market
Study Period:

2018 - 2026

Base Year:



8.1 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The North America clinical trials market is expected to register a CAGR of 8.1% during the forecast period. The market will show rapid growth due to the demand for clinical trials in the emerging markets, high R&D expenditure of the pharmaceutical industry and the rising prevalence of diseases.

In emerging countries, there are numerous unmet needs of clinical trials for novel drugs, due to the increasing prevalence of infectious and tropical diseases in the region. The population is found to have has varied disease profile which is increasing with the span of time and this is expected to boost the clinical trials of new or rare diseases. Therefore the number of patients having a specific disease would act as a stimulus for biopharmaceutical companies to invest more in clinical trials for a disease segment.

According to the National Clinical Trials Registry (NCT), in 2020, there are approximately 11,865 active clinical trials under development across different phases for cancer indication in the United States.

The research and development (R&D) spending of pharmaceutical companies has also been steadily increasing over the past few years. This was mainly due to numerous patent expiries, and as a result of the patent expiration, there are many pharmaceutical companies that will have no other option but to develop new drugs. Therefore, the companies are spending more on R&D to accelerate the development of drugs through clinical trials, and henceforth increasing the overall market.

Scope of the Report

As per the scope of the report, clinical trials are experiments that are conducted under clinical research and follow a regulated protocol. These experiments are primarily performed to obtain data regarding the safety and efficacy of newly developed drugs. Clinical trial data is mandatory for drug approval, as well as for it to be introduced in the market. These trials are performed under three phases (I, II, and III), which depends upon various factors. This process is not only expensive, but also time consuming, and requires expertise at all stages. The North America clinical trials market is segmented by phase, design and geography.

By Phase
Phase I
Phase II
Phase III
Phase IV
By Design
Treatment Studies
Randomized Control Trial
Double Blind Trial Randomized Trial
Single Blind Trial Randomized Trial
Non-blind Randomized Trial
Adaptive Clinical Trial
Non-randomized Control Trial
Observational Studies
Cohort Study
Case Control Study
Cross Sectional Study
Ecological Study
North America
United States

Report scope can be customized per your requirements. Click here.

Key Market Trends

Phase III is the Largest Segment Under Phases that is Expected to Grow During the Forecast Period

The market is expected to be dominated by Phase III, with Phase I expected to witness the fastest growth. Phase III is one of the most critical phases assessing the effectiveness of the new intervention, as well as its value in clinical practice. The Phase I trial in the market studied is also expected to grow at a steady rate, due to the increasing number of investigative new drug (IND) applications filed. The government initiatives in the North American countries for the promotion of drug discovery and continuous technological innovations are expected to propel the market growth. According to the National Clinical Trials Registry (NCT), currently there are about 309 active clinical trials under phase III development for cardiovascular diseases in the United States. Thus, owing to above factors the segment is expected to show growth in coming years.

NA clinical tials.png

To understand key trends, Download Sample Report

Competitive Landscape

The North America Clinical Trials Market is fragmented competitive and consists of several major players. The major pharmaceutical companies are found making enormous investments in R&D, especially in the emerging nations, in order to gain opportunities for market growth in the major regions. The strategic partnerships among pharmaceutical companies and the CROs are expected to have a significant impact on the market's growth.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Demand for Clinical Trials

      2. 4.2.2 High R&D Expenditure of the Pharmaceutical Industry

      3. 4.2.3 Rising Prevalence of Diseases

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Skilled Workforce for Clinical Research

      2. 4.3.2 Stringent Regulations

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Phase

      1. 5.1.1 Phase I

      2. 5.1.2 Phase II

      3. 5.1.3 Phase III

      4. 5.1.4 Phase IV

    2. 5.2 By Design

      1. 5.2.1 Treatment Studies

        1. Randomized Control Trial

          1. Double Blind Trial Randomized Trial

          2. Single Blind Trial Randomized Trial

          3. Non-blind Randomized Trial

        2. Adaptive Clinical Trial

        3. Non-randomized Control Trial

      2. 5.2.2 Observational Studies

        1. Cohort Study

        2. Case Control Study

        3. Cross Sectional Study

        4. Ecological Study

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico


    1. 6.1 Company Profiles

      1. 6.1.1 Clinipace

      2. 6.1.2 Eli Lilly and Company

      3. 6.1.3 F. Hoffmann-La Roche Ltd

      4. 6.1.4 ICON PLC

      5. 6.1.5 IQVIA

      6. 6.1.6 Laboratory Corporation of America

      7. 6.1.7 Novo Nordisk AS

      8. 6.1.8 PAREXEL International Corporation

      9. 6.1.9 Pfizer Inc.

      10. 6.1.10 Pharmaceutical Product Development LLC

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The North America Clinical Trials Market market is studied from 2018 - 2026.

The North America Clinical Trials Market is growing at a CAGR of 8.1% over the next 5 years.

  • Novo Nordisk AS
  • ICON Plc
  • Eli Lilly and Company
  • Clinipace

Are the major companies operating in North America Clinical Trials Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!